# A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects

> **NCT02681861** · PHASE1 · COMPLETED · sponsor: **Astellas Pharma Europe B.V.** · enrollment: 74 (actual)

## Conditions studied

- Healthy Subjects
- Pharmacokinetics of ASP6294

## Interventions

- **DRUG:** ASP6294 Intravenous
- **DRUG:** ASP6294 Subcutaneous
- **DRUG:** Placebo Intravenous
- **DRUG:** Placebo Subcutaneous

## Key facts

- **NCT ID:** NCT02681861
- **Lead sponsor:** Astellas Pharma Europe B.V.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01
- **Primary completion:** 2016-12
- **Final completion:** 2016-12
- **Target enrollment:** 74 (ACTUAL)
- **Last updated:** 2017-01-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02681861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02681861, "A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP6294 Administered Intravenously or Subcutaneously in Healthy Young Male and Female Subjects". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02681861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*